Wockhardt Widens Miqnaf Access as Q2 Revenue Rises 24%
Wockhardt Miqnaf access widens after DCGI lifted a supply condition on the novel antibiotic, as Q2 FY27 revenue rose 24% to ₹969 crore on biotech growth.
BIOSIMILARS
India’s Pharma Exports Rise 4.9% to $16.14 Billion in H1 FY27 as Europe, ASEAN Offset Softer US Shipments
India’s pharmaceutical exports grew 4.90% to USD 16.14 billion in April–September 2026, Pharmexcil data shows. Q2 exports rose 3.05% to USD 8.04 billion, Europe climbed 9.66% to USD 3.29 billion, ASEAN rose 21.54% and bulk drugs grew 12.07%, while US shipments moderated.
Enzene Hands Romiplostim Biosimilar Programme to Adalvo, Will Keep Making It in Pune as Biologics CDMO
Swiss B2B pharma company Adalvo has acquired Pune-based Enzene’s romiplostim biosimilar programme referencing Amgen’s Nplate, while Enzene stays on as development and manufacturing partner and sharpens its focus on biologics CDMO services.
NPPA Publishes Revised MRPs for 543 Cancer Drug Brands, With Cuts of Up to 93% but Innovator Prices Unchanged
NPPA has released revised MRPs for 543 anti-cancer brands and packs under its 30% trade margin cap, effective 9 November, with generics and biosimilars cut by up to 93% while brands such as Avastin, Keytruda and nivolumab see no change.
Cipla Q2 FY27 Profit Falls 35% to ₹878 Crore as One India Posts Record Quarter and US Inhaler Pipeline Builds
Cipla’s consolidated net profit fell about 35% year-on-year to ₹878 crore in Q2 FY27 on revenue of ₹7,404 crore, but its One India business logged its highest-ever quarterly sales, margins improved sequentially, and the company is leaning on its US inhalation pipeline and a Keytruda biosimilar partnership for growth.
Biocon Secures Entry for Stelara Biosimilar Yesintek in Nine More Global Markets via Janssen Licence
A fresh licence agreement with Janssen Sciences Ireland lets Biocon commercialise Yesintek, its ustekinumab biosimilar, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan, subject to local regulatory approvals.
Sun Pharma to Acquire Organon in US$11.75 Billion Deal, Strengthening Global Healthcare Portfolio
Sun Pharmaceutical Industries Ltd. has announced the acquisition of Organon in a landmark US$11.75 billion transaction, marking one of the […]
The Future of Pharma: Innovation, Self-Reliance, and Skilling as Key Pillars
India’s pharmaceutical sector is entering a transformative phase, driven by innovation, digital technologies, regulatory reforms, and a renewed focus on […]
Mankind Pharma Appoints Dr. Tausif Ahmed as Senior Vice President & Head of Clinical Research and Biopharmaceutics
Mankind Pharma Ltd. has announced the appointment of Dr. Tausif Ahmed as its Senior Vice President & Head of Clinical […]
Cipla to set up first biosimilars unit costing nearly $91 million
Cipla, the Indian pharmaceutical has inked an agreement with Dube Trade Port Special Economic Zone, a business entity of KwaZulu-Natal, […]
Zydus Cadila collaborates with Eczacibasi Ilac Pazarlama Aims to increase reach in Turkish market via biosimilars & new products
The Ahmedabad-based drug firm Zydus Cadila and Turkey-based leading healthcare firm, Eczacibasi Ilac Pazarlama have signed a pact to market […]
